Skip to main
SRTS
SRTS logo

Sensus Healthcare (SRTS) Stock Forecast & Price Target

Sensus Healthcare (SRTS) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 0%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Sensus Healthcare Inc. demonstrated significant growth in its shipping operations, delivering 27 SRT systems in 3Q24, a notable increase from previous quarters, highlighting the company's expanding market reach and demand. The company's financial performance for FY2024 was strong, with total revenue of $41.8 million, reflecting a remarkable 71% year-over-year growth, coupled with a net income of $6.6 million, further reinforcing its solid financial position. Additionally, the successful signing of multiple Fair Deal Agreements, including one with a network of over 130 dermatology clinics, emphasizes the company's strategic initiatives poised to enhance revenue streams and solidify its foothold in the market.

Bears say

Sensus Healthcare faces significant investment risks that could hinder its financial performance, particularly concerning the commercial success of its SRT and TransDermalInfusion systems. The company's ability to penetrate the market successfully is threatened by potential reimbursement issues and increased competition in the health technology sector. Additionally, there is a risk of dilution which may negatively impact shareholder value and overall financial stability.

Sensus Healthcare (SRTS) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 0% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sensus Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sensus Healthcare (SRTS) Forecast

Analysts have given Sensus Healthcare (SRTS) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Sensus Healthcare (SRTS) has a Strong Buy consensus rating as of Jul 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sensus Healthcare (SRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.